omecamtiv mecarbil (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Heart Failure

Pending FDA approval for treatment of heart failure with reduced ejection fraction (HFrEF)

Next:

Pharmacology

Mechanism of Action

First-in-class cardiac myosin activator; improves myocardial function by directly augmenting cardiac sarcomere function

Enhances cardiac contractility by selective binding to and recruiting more cardiac myosin heads to interact with actin during systole; this action increases the number of active actin-myosin cross bridges during each cardiac cycle and consequently augments impaired contractility associated with HFrEF

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.